Kairos Pharma Ltd (KAPA) Q4 2025 Earnings Call Transcript

Why It Matters

The upcoming pivotal trial data could unlock a multi‑billion‑dollar market, while the near‑term cash constraint forces the company to secure financing to sustain its growth trajectory.

Key Takeaways

• Q4 revenue $34.1M, up 11.8% YoY.
• Net loss $102.2M; cash runway to Q2 2026.
• 2026 revenue guidance $130‑150M, XPOVIO $115‑130M.
• Phase III SENTRY readout expected March 2026.
• 75% physicians prefer selinexor‑ruxolitinib combo.

Pulse Analysis

Karyopharm’s latest earnings reveal a modest top‑line rebound anchored by XPOVIO, its oral XPO1 inhibitor, which grew nearly 10% in the quarter. The company’s disciplined cost cuts—R&D down 17% and SG&A down 16%—helped improve operating leverage, yet a $102 million GAAP loss and a cash balance of $64 million leave the firm with a runway that only reaches the second quarter of 2026. This liquidity pressure has prompted the executive team to explore a range of financing alternatives, from debt refinancing to strategic partnerships, to ensure sufficient capital for upcoming milestones.

The clinical horizon is the true catalyst for Karyopharm’s valuation. The Phase III SENTRY trial, evaluating selinexor combined with ruxolitinib in frontline myelofibrosis, is slated for a March 2026 readout. Early Phase I data showed a 79% SVR35 rate and an 18.5‑point improvement in total symptom score, far surpassing historical JAK‑inhibitor benchmarks. With approximately 20,000 prevalent U.S. myelofibrosis patients and a target of 4,000 high‑risk individuals, the company projects peak U.S. revenue approaching $1 billion, a figure that could dramatically shift its cash profile if the trial confirms efficacy and safety.

Beyond hematologic disease, Karyopharm is positioning its pipeline for broader oncology reach. The Phase III EXPORT EC042 trial targets p53‑wild‑type endometrial cancer, a segment where checkpoint inhibitors have limited activity. Positive mid‑2026 data could add a high‑margin maintenance indication to the XPOVIO franchise. Additionally, the next‑generation XPO1 inhibitor eltenexor, protected through at least 2034, is slated for expansion into polycythemia vera and essential thrombocythemia, further diversifying revenue streams. Investors will weigh the upside of these late‑stage programs against the immediate financing needs, making the next six months pivotal for Karyopharm’s market positioning.